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Background: Mouse mammary tumour virus (MMTV) is a betaretrovirus that infects rodent cells and uses mouse
tranferrin receptor 1 (TfR1) for cell entry. Several MMTV strains have been shown to productively infect, in addition
to murine cells, various heterologous cell lines including those of human origin, albeit less efficiently than murine
cells. Furthermore, there have been reports that the continued passage of MMTV in heterologous cell lines gives
rise to novel variants that are able to infect naive non-murine cells with higher efficiency than the parental virus.
Results: We show that MMTV(C3H), like other MMTV strains, that had undergone a number of replication cycles in
non-murine cells displayed an increased replication kinetic, as compared to parental virus, when applied on naive
human cells. Sequence analysis of several replication kinetic variants and the parental virus, together with calculation of
the ratio of non-synonymous to synonymous mutations at individual codons, revealed that several regions within the
viral genome were under strong positive selection pressure during viral replication in human cells. The mutation
responsible, at least in part, for the phenotypic change was subsequently mapped to the segment of env encoding the
receptor binding site (F40HGFR44). Introduction of the identified mutation, leading to single amino acid substitution
(G42E), into egfp-containing recombinant MMTV virions enhanced their ability to bind to and infect human cells.
Interestingly, neither the replication kinetic mutant nor the parental virus required human TfR1 for infection. Knock-out
of TFR1 gene from the human genome did not decrease the susceptibility of Hs578T cells to virus infection.
Furthermore, the expression of human TfR1, in contrast to mouse TfR1, did not enhance the susceptibility of
MMTV-resistant Chinese hamster ovary cells. Thus, human TfR1 is dispensable for infection and another cell surface
molecule mediates the MMTV entry into human cells.
Conclusion: Taken together, our data explain the mechanism enabling MMTV to form ‘host-range variants’ in
non-murine cells that has been known for a long time, the basis of which remained obscure. Our findings may
expand our understanding of how viruses gain capability to cross species-specific barriers to infect new hosts.
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Cross-species transmission of viruses is well documented.
Understanding how viruses infect and spread in new hosts
is central to understanding the pathogenesis of infection
and emergence of disease. Mouse mammary tumour virus
(MMTV), the prototypical Type B betaretrovirus, infects
Muridae rodents (of the Mus genus specifically) and is
associated with mammary adenocarcinomas and T-cell
lymphomas [1-4]. Mouse transferrin receptor 1 (mTfR1) is
used by MMTV to initiate infection of murine cells [5].
The human ortholog (hTfR1), even though it has been re-
ported to bind MMTV efficiently, does not serve as an
entry receptor for MMTV [6]. Virus entry was blocked at
a post-attachment phase due to a lack of internalization of
MMTV-bound hTfR1 and subsequent trafficking to the
late endosomes where fusion of membranes occurs [6].
Interestingly, although the virus cannot use hTfR1 for cell
entry, several MMTV strains have been shown to product-
ively infect, in addition to murine cells, various heterol-
ogous cell lines including those of human origin, albeit
less efficiently than murine cells [7-11]. It has also been
reported that MMTV sequences have been detected in
human breast cancer and primary biliary cirrhosis spec-
imens [12-17], as well as in canine and feline neoplastic
and normal mammary tissue [11].
Recent reports also showed that MMTV-like viruses have
once circulated more widely among rodents and other
mammalian species. This belief comes from the identifica-
tion of MMTV-like endogenous retroviruses (ERVs, fossils
of now extinct viruses integrated into the genome of their
host species) in rodent populations devoid of infectious
MMTV and in other mammalian hosts of wide geographic
and evolutionary diversity [18,19].
Additional evidence further supporting the notion that
MMTV may be able to cross the species barrier and that
MMTV–like viruses once circulated more widely among
rodents is based on evolutionary analysis of rodent TfR1
amino acid residues that interact with MMTV-like virus
envelope. These residues have undergone positive selection
for mutations that compromise the interaction between
the betaretrovirus entry glycoprotein and TfR1 [18]. At the
same time, the entry glycoprotein receptor binding site
(RBS; F40HGFR44 residues at the N-terminus-proximal re-
gion of the MMTV surface subunit (SU) domain [20]) has
evolved to acquire compatibility with particular host TfR1
orthologs [18]. The molecular arms race between MMTV
Env and rodent TfR1 driving endless rounds of ‘positive se-
lection’ for mutations that affect interaction between the
virus and host as well as above mentioned evidence sup-
port the concept that MMTV-like viruses once circulated
more widely in nature and that they are particularly adept
at overcoming cellular barrier preventing cross-species
transmissions. Consistent with this model is the obser-
vation that continuous passage of MMTV in human orfeline cell lines results in an adapted virus that infects
various non-murine cells more efficiently that the parental
virus [21,22]. At present, the nature of the adaptation
mutation(s) responsible for this phenotypic change is un-
known, however it can be envisaged that changes in the
receptor binding site may allow the emergence of host
range variants.
Such a scenario would be reminiscent of that reported
for viruses belonging to two other virus families, Parvovir-
idae (canine and feline parvoviruses) and Arenaviridae
(several rodent and human arenaviruses), which also use
TfR1 as their primary cellular receptor to trigger their
cellular entry. Canine parvovirus type 2a, is a host-range
variant of the closely related feline parvovirus that gained
access to dogs through the acquisition of only a few muta-
tions in the capsid protein that allowed efficient binding
of the virus to TfR1 expressed on the surface of canine
cells [23,24]. It now appears that the transmission from
cats to dogs was an indirect event involving passage
through another carnivore species, racoon, which contrib-
uted to the adaptation of the capsid protein to canine
TfR1 and the emergence of the canine parvovirus [25].
There is also indirect evidence suggesting that New World
arenaviruses are able to, though minor changes in the
arenavirus entry glycoprotein, expand their host range.
Several of these viruses, which typically circulate in ro-
dent species found in the Americas, are emerging into
human populations, where they cause hemorrhagic fever
and lethal disease [26,27]. Their zoonotic potential cor-
relates with the ability to use the human TfR1 (hTfR1)
in addition to their native rodent TfR1 [26]. Whereas
clade B arenavirus that do not cause human disease (e.g.
Amapari virus and Tacaribe virus) cannot utilize hTfR1 for
cell entry, the pathogenic clade B arenaviruses effectively
recognise the human ortholog, leading to the more ef-
ficient infection of human cells and, in turn, zoonotic
transmission [28-30]. Interestingly, it has been shown
that changes in as little as one amino acid residue of
hTfR1 were sufficient for nonpathogenic arenaviruses
to gain use of the receptor for cell entry [29]. Similarly,
mutation of only a few amino acid residues enabled the
conversion of the mouse TfR1 (mTfR1) to a compatible
cell entry receptors for pathogenic arenaviruses [28]. From
the aforementioned studies, it can be inferred that only
minor changes in the receptor binding domain of GP1
may dramatically change arenavirus tropism.
Using both a wild-type and a recombinant egfp-
containing virus carrying MMTV(C3H) Env, we have
recently shown that MMTV(C3H), like other strains,
is able to infect human cells, albeit less efficiently than
mouse cells [31]. The established infection was, however,
sufficient to enable virus spread to every cell in culture. In-
fectivity of the wild-type and MMTV(C3H)-Env-carrying
MMTV recombinant virions was blocked by heat-
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3′-azido-3′-deoxythymidine (AZT), ruling out a non-
specific mechanism of viral transfer [31]. Furthermore, in-
fection requires an intact MMTV envelope protein, since
neutralizing anti-MMTV antibodies blocked infectivity of
both the wild-type and MMTV(C3H)-Env-carrying MMTV
recombinant virions. Persistently infected Hs578T cells pro-
duced infectious virus particles capable of infecting naive
human breast cells in culture, the infectivity of which could
be blocked by neutralizing anti-MMTV antibodies, heat-
inactivation and AZT, demonstrating that virus particles re-
leased by the persistently infected Hs578T cells are antigen-
ically related to the virus produced from murine cells and
showing that the presence of proviral DNA in infected
cells is due to an authentic, receptor-mediated and re-
verse transcriptase-dependent infection process [31].
Herein, we analyse whether the replication of MMTV
(C3H) in human cells results in sequence alterations
that facilitate its spread and survival in the new host.
Consistent with previous reports we show that the
replication of MMTV in non-murine cells leads to the
formation of variants that replicate faster in human
cells. Furthermore, we demonstrate that the mutation
responsible, at least in part, for the phenotypic change
is located in the receptor binding site of the viral
glycoprotein. Finally, we present evidence showing
that the human TfR1 is not required for more efficient
infection of human cells with the replication kinetic
mutant, suggesting that the virus has adapted to use
another cell surface molecule for cell entry.
Results
MMTV(C3H) particles released by the persistently infected
human cells exhibit an accelerated cell-to-cell spread
phenotype in human cells
Previously, we have shown that wild-type MMTV(C3H)
and a recombinant EGFP containing virus carrying
MMTV(C3H) Env could infect cultured human cells via a
specific interaction of the viral envelope with the cell
surface receptor [31]. Additionally, the wild-type virus
[MMTV(C3H)], harvested from cell culture fluids of
an MMTV-induced mouse mammary tumour cell line
(Mm5MT), was able to replicate in a human mammary
epithelial cell line (Hs578T), ultimately leading to the
infection of every cell in culture [31]. These persistently
infected human Hs578T cells produced infectious virus
particles [designated MMTV(C3H)hp1] capable of infect-
ing naive human breast cells in culture. The infectivity
of MMTV(C3H)hp1 was blocked by neutralizing anti-
MMTV antibodies, demonstrating that virus particles
released by the persistently infected human cells are an-
tigenically related to the virus produced from murine
cells [31]. Here we have extended this earlier work by
addressing the question of whether MMTV(C3H)hp1 isable to productively replicate in human breast cells and
whether the replication kinetics of the virus in non-
murine cells changed relative to the parental virus.
For this set of experiments, cell free virus obtained from
cell culture fluids of human cells persistently infected with
MMTV(C3H) (6 weeks post infection) or wild-type virus
obtained from cell culture fluids of an MMTV induced
mouse mammary tumour cell line derived from the C3H/
HeN mouse strain (Mm5MT) [32] was used to infect
naive, uninfected Hs578T cells. Prior to infection, virus
particle titers were determined by real-time TaqMan
RT-PCR targeting the 5′ end of env and normalized virus
levels were used for infection of human cells. Quantifica-
tion of proviral DNA one week post infection, using real-
time TaqMan PCR, showed approximately equivalent
proviral load in the infected cells. Next, the cells were
cultured in the presence or absence of DEX (10−6 M)
and gDNA was extracted at regular time points.
In agreement with our previously published data [31], in-
creasing levels of proviral DNA were detected within Hs578T
cells infected with MMTV(C3H) over time (Figure 1A & E),
as assessed by semi-quantitative (targeting the MMTV
LTR-gag region) and quantitative (targeting the 5′ end
of the env coding region) PCR. Importantly, an increase
in proviral DNA levels was also detected for cells infected
with MMTV(C3H)hp1 (Figure 1B & E). Interestingly,
the infectious particles released by the persistently infected
human cells, MMTV(C3H)hp1, showed an increased
replication kinetic in human cells compared to viruses
produced from Mm5MT cells. Specifically, all Hs578T
cells infected with MMTV(C3H)hp1 carry a copy of the
proviral DNA at 21 days post infection (Figure 1E). In
contrast, Hs578T cells infected with MMTV(C3H) need
to be cultured for at least 80 days before all cells carry
a copy of the proviral DNA (Figure 1E). The increase
was dependent on the presence of DEX in the cultivation
medium, since no noticeable augmentation of proviral
DNA levels was detected in cells cultured in the absence
of DEX (Figure 1C, D and E).
Collectively, these findings show that MMTV(C3H)hp1
virus produced from persistently infected human cells is
not only able to replicate in naive human cells, but also
exhibits a faster replication kinetic in human cells.
Sequence analysis of the virus replicating in human cells
Next, we determined twelve complete MMTV(C3H)hp1
proviral sequences (minus the gag gene, which contains
a sequence precluding cloning and growth in E. coli) and
compared them to MMTV(C3H) sequences identified in
virus preparations from murine mammary carcinoma cells.
No recombination events with sequences of human origin
were identified in the proviral sequences derived from
viruses that have undergone several replication cycles
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Figure 1 Quantification of proviral DNA in cell lysates of first and second round infected human Hs578T cells during a time-course experiment.
Hs578T cells infected with either MMTV(C3H) (A & C) or MMTV(C3H)hp1 (B & D) were cultured in the presence or absence of 10−6 M DEX. Genomic
DNA extracted from infected cells at the indicated time points and semi-quantitative PCR performed. -ve: non-transduced Hs578T cells. +ve: producer
cells. Equal DNA loading was controlled in the PCR assay with GAPDH-specific primers (bottom panels). Real-time TaqMan PCR was performed for an
accurate quantification of proviral loads in infected Hs578T cells (E), during the time-course experiment. Equal loading of the PCR reactions
were quantified in a real-time TaqMan PCR specific for the APOB gene.
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cells was a variant resulting from recombination with
mouse genomic sequences, including the endogenous
Mtvs.
Several nucleotide substitutions were detected in the
pro (a portion), pol, env and sag genes (data not shown).
The greatest number of point mutations was found in
the Env coding region. Next, we sought to analyze whetherselection pressures shaped the genetic variation during
cultivation in human cells. Calculation of the ratio be-
tween the number of non-synonymous mutations per
non-synonymous site (dN) and synonymous mutations
per synonymous site (dS) was used to infer the direction
and magnitude of natural selection acting on a protein
encoding sequence. A dN/dS ratio lower than one im-
plies purifying selection, whereas a ratio greater than
Konstantoulas et al. Retrovirology  (2015) 12:43 Page 5 of 19one implies positive or fixing selection. The ratio was
calculated using the Tamura-Nei method implemented
in the MEGA software package that estimates the num-
ber of non-synonymous and synonymous changes that
have occurred at each codon throughout evolution [33].
The average dN/dS ratio for the entire Env coding
region was slightly less than one, suggesting that the
entire env is under neutral selection. However, because
different regions of a single gene can be exposed to differ-
ent selective pressures, we analysed the dN/dS ratios over
the entire length of the gene using a sliding window of
100 codons. Importantly, several regions in env were
found to be under positive selection during virus culti-
vation in human cells (Figure 2A, left panel). These include
segments of the env gene encoding the signal peptide, the
receptor binding domain (RBD) at the N-terminus of the
SU domain, the central part of SU and the N-terminal part
of TM domain [20] (Figure 2A, right panel). Identification
of a positive selection pressure for the RBD may be of par-
ticular interest as non-synonymous mutations in this re-
gion, which mediates interaction between the virus and
receptor(s) on the cell surface, may alter virus tropism and
facilitate infection of human cells. Interestingly, one of the
nt substitutions leading to a non-conservative amino acid
substitution (glutamic acid in place of glycine at position
42 of SU; G42E) in a five-amino-acid stretch of polar and
hydrophobic residues, F40HGFR44, believed to constitute
the receptor binding site (RBS) [20], was detected in all
twelve MMTV(C3H)hp1 clones but not in MMTV(C3H)
virus (Figure 2B and C). This particular polymorphism has
previously been reported in the SU sequence from
MMTV(RIII) virus adapted to the human breast cancer
cell line MCF-7 (designated RIIIM) [20,34]. Additionally,
one of the twelve MMTV(C3H)hp1 clones was also found
to carry an additional non-synonymous mutation (arginine
to lysine substitution at position 44 of SU; R44K) in the
RBS of SU (Figure 2B). These results imply that the RBD
of viruses replicating in human cells is under positive se-
lection pressure and changes in this region may facilitate
infection of human cells and in turn lead to faster replica-
tion kinetics. Other point mutations leading to amino acid
substitutions were found outside the regions encoding the
RBD and heparin binding domain (HBD). In contrast to
the mutations described above, none of these polymor-
phisms were found in all twelve MMTV(C3H)hp1 clones.
Surprisingly, a high frequency of non-synonymous
mutations was also identified for the Sag coding region
(Figure 2A, left panel). This region also appears to be under
a positive selection pressure. The reason for the observed
phenomenon is not clear. As expected, the most conserved
gene was the gene encoding the enzymatic components of
the virus, pol. The dN/dS ratio for this region was close to
one, suggesting that this segment of the virus was under
neutral selection (Figure 2A, left panel).Virus replicating in human cells carries a human
APOBEC3G signature of cytosine deamination
Next, we analysed whether the MMTV(C3H)hp1 se-
quences carry a signature of the human APOBEC3G
(hA3G), which is expressed in Hs578T cells [35]. The
hA3G is an intrinsic immunity factor that catalyses de-
amination of deoxycitidine (C) to deoxyuridine (U) in
the minus strand viral DNA (−ssDNA) during reverse
transcription. (Subsequent synthesis of the plus strand
from a deaminated minus strand template induces G to
A mutations in newly generated plus strand viral DNA).
We hypothesised that if the variants exhibiting faster rep-
lication kinetics resulted from the mutagenesis in human
cells and not from selection of pre-existing quasispecies,
they should contain hallmarks of hA3G-mediated muta-
genesis (C to U transitions in the -ssDNA). Furthermore,
analysis of sequence context of the deaminated deoxyciti-
dines can be also used as an indirect method to confirm
the human origin of infected cells. This is due to the fact
that the hA3G and mouse APOBEC3 deaminases target
deoxycytosine within different DNA sequence contexts
(hA3G commonly targets the last C in a run of C’s on the
-ssDNA, whereas mouse APOBEC3 prefers “TTC” targets
[36-38]). We observed that about 40% of mutations could
be attributed to APOBEC3 activity (Figure 3A; C to T
substitutions in the –ssDNA). Additionally, the most
commonly targeted cytosine was within the canonical
5′-CCC-3′ (−ssDNA) sequence context recognized by
hA3G (Figure 3B). Importantly, the hA3G activity also
likely accounted for the G42E substitution in the receptor
binding sequence detected in all twelve MMTV(C3H)hp1
clones. The glycine codon GGG (CCC in -ssDNA) was
mutated to GAG (CUC in –ssDNA) encoding for glu-
tamic acid. Taken together, these data provide evidence
supporting the concept that a large proportion of muta-
tions in MMTV(C3H)hp1 proviral DNA can be attributed
to hA3G-directed mutagenesis. Hallmarks of the hA3G-
mediated cytosine deamination substantiate our original
hypothesis that MMTV(C3H) is capable of productive in-
fection of human cells. Additionally, the hA3G-mediated
mutagenesis may, at least in part, explain the relatively
long cultivation time required to detect infection of every
human cell in culture.
G42E alters the tropism of egfp-containing MMTV-based
vectors
To find out whether the G42E mutation facilitates infec-
tion of human cells, the mutation was introduced into
the MMTV(C3H) Env construct (pENVC3H). The wild-
type and mutant ENVs were subsequently used to gener-
ate egfp-carrying MMTV recombinant virions, using an
MMTV-based vector system analogous to the third
generation of lentiviral vector production systems [39].
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Figure 2 Sequence analysis of MMTV(C3H)hp1 from the second round infected Hs578T cells. Genomic DNA isolated from Hs578T cells 2 weeks
after infection with MMTV(C3H)hp1 or cDNA synthesised from RNA extracted from filtered producer cell (Mm5MT) culture medium was used for
amplification and cloning of the entire MMTV genome, minus the gag gene. (A) The ratio between the number of non-synonymous mutations
per non-synonymous site (dN) and synonymous mutations per synonymous site (dS) was calculated using the Tamura-Nei method implemented
in the MEGA software package that estimates the number of non-synonymous and synonymous changes that have occurred at each codon
throughout evolution [33]. In the right panel, the dN/dS ratio for subregions in the MMTV env analysed using a sliding window of 100 codons is
shown. (B) Sequence alignment of amino acid residues 1 through 72 of MMTV SU of two virus clones [MMTV(C3H)] and twelve proviral clones
[MMTV(C3H)hp1] were aligned. Mtv-1 (AF228550.1), Mtv-2, Mtv-8 (M22028.1), Mtv-17 (AF263910.1), MMTV(C3H-HeN) (AF228552.1), MMTV(C3H-HeJ)
(AF2258551.1), MMTV(RIII) (AF071010.1) and MMTV(BR6) (M15122.1) sequences were also included in the alignment. The coordinates of the MMTV
Env amino acid sequence are according to Zhang et al. [20]. Potential N-glycosylation sites (GS) are highlighted in light green and RBS in yellow.
(C) Predicted 3D structure of the MMTV SU in space-filled form generated using Swiss-Model is shown. The RBS is indicated in yellow, the
glycosylation site in green, basic residues in blue and acidic residues in red. In the right panel, the RBS is enlarged and the charge change
caused by G to E substitution at position 42 is highlighted.


































































Figure 3 Virus replicating in human cells carries a human APOBEC3G signature of cytosine deamination. Nucleotide sequences obtained as described in
Figure 3 were examined for the presence of hAPOBEC3G-mediated nucleotide changes on minus sense DNA. (A) All possible nucleotide transversions
and transitions detected in the pro (a portion), pol, env and sag genes are expressed as a percentage of total number of nucleotide substitutions. (B) All
C-to-T mutations found in the minus sense DNA strand were analysed for sequence context at the −1 and −2 nucleotide position.
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particles were generated by cotransfection of HEK293T
cells with an MMTV-based vector construct containing
egfp gene, together with a packaging construct, an HIV-1
Rev expression construct and finally a plasmid expressing
the WT (C3H) or mutant (G42E) envelope protein. As a
control, we used MMTV particles pseudotyped with an
amphotropic MLV 4070A Env. The filtered supernatant
from transfected HEK293T cells was subsequently used to
transduce both human (Hs578T) and mouse (NMuMG)
mammary epithelial cells.
We first demonstrated that the mutant Env was effi-
ciently processed. Total cell extracts from WTand mutant
pENVC3H-transfected HEK293T cells were subjected to
Western blot analysis with anti-gp52/36 to determine the
levels of the viral proteins. The mutant Env was processed
into mature SU and TM (Figure 4A), indicating that no
gross changes in Env processing had occurred as a result
of the sequence alterations.
The viruses were next tested for their ability to trans-
duce Hs578T & NMuMG cells. When equal amounts of
virus (quantified by western blot analysis of serially diluted
concentrated virions using anti-MMTV CA antibody)
were used for transduction of human cells, the G42E
mutant exhibited approximately 6-fold increase in trans-
duction efficiency compared to WT Env carrying virus
(Figure 4B). In mouse cells, however, the same mutations
caused only a modest (~2-fold) increase in transduction
levels (Figure 4B). The infectivity of MMTV-based vectors
carrying the mutant Env was, like the infectivity of vectors
carrying the WT Env, completely blocked after pre-
incubation with neutralizing goat anti-MMTV antibodies
(Figure 4C). In contrast, pre-treatment of the virions with
non-specific serum had no effect on the infectivity
(Figure 4C). Importantly, no alteration in the infectivitywas observed when the MLV 4070A Env-carrying pseu-
dovirions were pre-incubated with the anti-MMTV
antibodies (Figure 4C), ruling out nonspecific infection
inhibition activity of the serum. Additionally, the infect-
ivity of the WT and mutant Env-carrying MMTV virions
was blocked by heat-inactivation (60°C, 10 minutes) and
an inhibitor of reverse transcription, 3′-azido-3′-deox-
ythymidine (AZT; 37 μM) (Figure 4C), ruling out a non-
specific mechanism of vector transfer/showing that vector
transfer is due to an authentic, reverse transcriptase-
dependent infection process.
Collectively, these data imply that G42E mutation is,
at least in part, responsible for the adaptation of MMTV
(C3H)hp1 to new host. Additionally, specific neutralization
of vector infectivity demonstrates that mutant Env parti-
cles, like WT Env particles, rely on a specific interaction of
the viral envelope with the cell surface receptor to mediate
infection of human cells.
G42E mutation does not enhance affinity to heparan sulfate
Viruses from different families (including retroviruses)
that have undergone multiple passages in cell culture have
been shown to exhibit a higher affinity for the glycosami-
noglycan heparan sulfate (HS) [40-45]. To test whether
the G42E mutation conferred an HS-binding phenotype,
wild-type and mutant recombinant virus-containing su-
pernatants were incubated in the presence or absence
of increasing amounts HS and then used to transduce
Hs578T cells. In agreement with previously published
data [20], treatment of wild-type virus with soluble HS
resulted in a dose-dependent decrease in infectious
titers, demonstrating that binding to HS on the cell
surface plays a role in MMTV infection (Figure 4D). Im-
portantly, increasing amounts of HS caused a similar de-























































































































































Figure 4 Mutation of a single amino acid in the RBS alters the tropism of egfp-containing MMTV-based vector. (A) MMTV Env carrying G42E mutation
is expressed and cleaved into SU (gp52) and TM (gp36) subunits. Equivalent protein content (10 μg) of whole cell extracts from wild-type and mutant
pENVC3H-transfected HEK293T cells were subjected to SDS-PAGE followed by Western blotting analysis with anti-gp52/36 (1:12000). (B) Target cells
(Hs578T or NMuMG) were transduced with MMTV-based vector particles carrying wild-type or mutant MMTV(C3H) envelope. Transduction levels were
made relative to the value obtained for MMTV-based vector particles carrying wild-type Env and expressed as a percentage of that control. The values
shown are mean ± standard errors from three independent experiments. The inset shows a Western blot of 10 μl of each concentrated virus
preparation probed with polyclonal anti-MMTV-CA antiserum (1:4000). (C) Hs578T cells were transduced with MMTV vectors carrying wild-type
MMTV(C3H) Env, mutant MMTV(C3H) Env or MLV 4070A Env. Neutralization, heat inactivation and AZT treatment were performed as described
in materials and methods. Transduction levels were made relative to the value obtained for the infected cells and expressed as percentage of
that control. The values shown are mean ± standard errors from three independent experiments. (D) MMTV-based vector particles carrying either wild-type
or mutant MMTV(C3H) Env were incubated with the indicated amount of heparan sulfate, and mixture was subsequently used to transduce Hs578T cells.
Transduction levels were made relative to the value obtained in the absence of heparan sulfate and expressed as a percentage of that control. The values
shown are mean ± standard errors from three independent experiments. Transduction was detected by flow cytometry (FCM) 3 days post infection. The
number of eGFP expressing cells was counted using forward scatter vs. fluorescence intensity in the FL1 channel (eGFP) plots.
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conservative G42E mutation was not due to enhanced
interaction with proteoglycans (Figure 4D).
G42E mutation enhances virus binding to human cells
The increased infectivity of G42E mutant could be due
to increased Env binding to its receptor or to alterations
that affect subsequent steps in the infection pathway,
such as membrane fusion. In an attempt to differentiate
between the two possibilities virus-binding assays were per-
formed. Hs578T and NMuMG cells were incubated with
equal amounts of wild-type or mutant virions, stained with
anti-MMTV antiserum and analysed by flow cytometry(FCM) to detect bound virus. Virus carrying the mutant
MMTV Env bound human cells (Hs578T) more efficiently
than virus carrying WT Env (Figure 5A). No difference in
binding efficiency was observed for WT and mutant Env
in NMuMG cells (Figure 5A).
To further corroborate the results, we analysed whether
the virus carrying the mutant envelope is, due to tighter
binding to the cell surface, less efficiently egressed from
producer cells. Vectors, containing either the WT or
mutant (G42E) Env, constitutively released from transfected
cells and vectors trapped at the cell surface (released fol-
lowing subtilisin A treatment) were quantified by Western

















































Virus Particles Cell Lysates
Coomassie
subtilisin A:   - +     - +       - - -
Figure 5 G42E enhances virus binding to human cells. (A) Equal amounts of MMTV-based vector particles carrying either wild-type or mutant
(G42E) MMTV(C3H) Env were incubated on ice with either Hs578T or NMuMG cells. The cells were stained with anti-MMTV antiserum, followed by
FITC-conjugated secondary antibodies and subjected to FCM. Dead cells were excluded by their forward scatter/side scatter properties. Binding
levels were made relative to the value obtained for MMTV-based vector particles carrying wild-type Env and expressed as a percentage of the controls.
The values shown are mean ± standard errors from three independent experiments. (B) Supernatants (left panel) from HEK293T cells cotransfected with
packaging construct (pCMgpRRE17), an egfp-containing MMTV vector plasmid (pRRpCeGFPWPRE25), a Rev expression construct (pLP2) and either the
wild-type or mutant MMTV(C3H) Env were harvested before and after subtilisin A treatment and virions pelleted by ultracentrifugation. 10 μl of the
resuspended pellets was subjected toWestern blotting with anti-MMTV-CA antibodies. Cell lysates (right panel) of the virus producers before
subtilisin A treatment were analysed by Western blotting. Equivalent protein loading was verified by Coomasie staining (bottom panel). The
experiment was performed three times with similar results; a representative experiment is shown.
Konstantoulas et al. Retrovirology  (2015) 12:43 Page 9 of 19of the WT MMTV Env virions were released into the
supernatant (Figure 5B, left panel, WT subtilisin A -)
with relatively low amounts of virus trapped at the cell
surface of producer cells (Figure 5B, left panel, WT sub-
tilisin A +). In contrast, for mutant MMTV Env, a
higher amount of virus was retained on the cell surface of
producer cells (~4-fold more than amounts found for WT
MMTV Env; Figure 5B, left panel, G42E subtilisin A +),
which was also reflected by the lower amounts of constitu-
tively released virus detected in the supernatant (Figure 5B,
left panel, G42E subtilisin A -; and Figure 4B, inset).
Collectively, these data suggest that the non-conservative
G42E mutation enhances the interaction between virus
particles and their receptor(s) on the cell surface.
Infection of human cells does not require expression of hTfR1
Next, we analysed whether the non-conservative G42E
mutation, which alters the charge at RBS, allows
MMTV to use hTfR1 for cell entry. Such a scenario
would be reminiscent of what has been reported for
New World clade B Arenaviruses, several of which
have, through minor changes in the amino acid resi-
dues of the RBD, acquired compatibility with hTfR1,
and are emerging into human populations through zoo-
notic transmission [26,46].
Chinese hamster ovary (CHO) cells, used for the identi-
fication of the MMTV receptor, were transfected with
plasmids expressing the human and mouse TfR1, respect-
ively. These cells were subsequently transduced with eGFPexpressing MMTV-based vectors carrying either WT or
mutant (G42E) Env. As controls, MMTV-based vectors
pseudotyped with either the Junin (JUNV; pathogenic
clade B arenavirus) or the Tacaribe (TCRV; non-pathogenic
clade B arenavirus) glycoprotein (GP) were included. The
GPs from pathogenic New World clade B arenaviruses
use hTfR1 as a cellular receptor, whereas non-pathogenic
strains do not use hTfR1 for cell entry [28-30,46]. mTfR1,
on the other hand, plays no role in clade B arenavirus cell
entry [28-30].
As expected, the expression of hTfR1 in CHO cells
resulted in a significant increase in the transduction
levels of MMTV-based vectors pseudotyped with JUNV
GP (~5-fold; Figure 6A) but did not affect the transduc-
tion rates of the vectors pseudotyped with TCRV GP
(Figure 6A) [29,30,46]. Further, the addition of mTfR1
had no effect on the transduction efficiency of either
JUNV or TCRV GP pseudotyped vectors (Figure 6A).
In contrast to arenaviruses, mTfR1 expression caused a
significant increase in the transduction levels of MMTV-
based vectors carrying WT and G42E Env, respectively
(>10 fold; Figure 6A). Importantly, the expression of
hTfR1 had no effect on transduction efficiency (Figure 6A).
Similar results were also obtained when wild-type
MMTV(C3H) virus, harvested from cell culture fluids
of an MMTV-induced mouse mammary tumour cell
line (Mm5MT) was used (Additional file 1: Figure S1A).
Also in this case only the presence of mTfR1 allowed effi-









































Figure 6 MMTV infection is not mediated through human transferrin receptor 1. (A) CHO cells transfected with mTfR1 or hTfR1expression plasmids
were transduced with MMTV-based vector particles carrying the wild-type (WT) or mutant (G42E) MMTV(C3H) Env, or MMTV cores pseudotyped with
clade B arenavirus GPs (Junin virus, JUNV; Tacaribe virus, TCRV). Expression of hTfR1 was confirmed by western blotting (inset); mTfR1 was not recognised
by the α-TfR1 antibody (ab137944, Abcam). (B) Hs578T cells transfected with hTFR1-specific siRNA or non-targeting siRNA were transduced
with MMTV-based vector particles carrying the wild-type (WT) or mutant (G42E) MMTV(C3H) Env, or MMTV cores pseudotyped with clade B
arenavirus GPs. hTfR1 knock-down was confirmed by western blotting (inset). (A & B) Transduction of target cells was detected by FCM 3 days
post infection. Transduction levels were made either relative to the value obtained for control siRNA (A) or relative to the value obtained for
the mock-transfected cells (B) and expressed as percentage of those controls. The values shown are mean ± standard errors from three
independent experiments.
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hTfR1 expression will have an effect on transduction effi-
ciency. Hs578T cells were treated with an hTFR1
mRNA-targeting siRNA prior to incubation with MMTV
vectors carrying various Envs. As a control, cells trans-
fected with non-targeting siRNA were used. Similar to
previous reports, the depletion of hTfR1 in Hs578T cells
resulted in approximately 2-fold reduction in the trans-
duction levels of JUNV GP pseudotyped vectors, whereas
the levels of TCRV GP pseudotyped vectors remained
unaffected (Figure 6B) [30]. Importantly, the transduc-
tion efficiency of MMTV Env-carrying vectors under
conditions of reduced endogenous hTfR1 expressionremained comparable to that obtained with cells
expressing hTfR1. Similar results were observed for
both the WT and mutant Env (Figure 6B). The infect-
ivity of wild-type MMTV(C3H) virus, harvested from
Mm5MT cells, was also unaffected by hTfR1 knock-
down (Additional file 1: Figure S1B).
Taken together, these results show that mTfR1 can serve
as receptor mediating entry of wild-type virus and vectors
containing the wild-type as well as G42E Env. Further-
more, the presented evidence suggests that MMTV vari-
ants carrying G42E mutation, although they exhibit greater
infectivity in human cells, do not use hTfR1 to mediate
their entry into human cells.
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Knock-down of hTFR1 did not result in complete elim-
ination of the hTfR1 protein expression. Therefore, it
may be possible that residual levels of hTfR1 may affect
the MMTV entry process. For example, remaining
hTfR1 may be sufficient to initiate a low level of virus
entry. Alternatively, as MMTV binds to hTfR1 [6], the
presence of the protein on the cell surface may trap
the virus and/or hinder its interaction with other mole-
cules on the cell surface. To provide a definitive answer
as to whether hTfR1 has any role to play in MMTV in-
fection, we knocked out hTFR1 from Hs578T cells,
using CRISPR (Clustered Regularly Interspaced Short
Palindromic Repeats Type II)/Cas9 [47,48]. Specifically,
we used the lentiCRISPR vector production system,
which enables simultaneous delivery of a mammalian
codon-optimised Cas9 nuclease, a single guide RNA
(sgRNA) and a puromycin selection marker into target
cells [49].
To test the efficacy of the gene knock-out by lenti-
CRISPR transduction, a sgRNA targeting egfp was cloned
into the LentiCRISPR plasmid. The LentiCRISPR plas-
mid was transfected into HEK293T cells together with
a packaging vector, an HIV rev expression construct
and a vector encoding the vesicular stomatitis virus
(VSV-G) Env to generate replication-defective lentiviral
vectors for transduction. The filtered supernatants from
transfected HEK293T cells were subsequently used to
transduce Hs578T cells expressing EGFP. Following
11 days selection with puromycin, lentiCRISPR abol-
ished EGFP fluorescence in the majority (~98%) of
cells, as determined by flow cytometry analysis (data
not shown).
For targeted hTFR1 knock-out, sgRNA targeting a se-
quence within the 6th exon of hTFR1 was cloned into
the LentiCRISPR plasmid and used for transduction of
Hs578T cells (Figure 7A and B). Transduced cells were
cultured in the presence of puromycin for a total of
14 days after which individual clones were isolated and
expanded. A total of 43 clones were used for further
analysis. First, we assayed the genomic mutation status
of the hTFR1 locus in the individual clones. The
CRISPR-Cas9 system induces double-strand DNA
breaks that are repaired mainly by error-prone non-
homologous end joining (NHEJ). Thirty three percent
(14 out of 43) of the clones bore mutations at the
hTFR1 locus, as determined by a T7 endonuclease I
(T7EI) assay and DNA sequencing (Figure 7C). Of the
14 clones, one contained mutations in all three copies
of the hTFR1 locus [Hs578T cells carry two copies of
chromosome 3 as well a derivative of chromosome 3:
der(3)t(3;15)(q10;p10); hTFR1 gene located on Chr3q29],
as determined by DNA sequencing (Figure 7E). These
mutations led to premature stop codons, which effectivelydisrupted the open reading frame (ORF) of hTFR1, yield-
ing truncated protein products (Additional file 2: Figure
S2). Successful hTfR1 knock-out was confirmed by
western blotting of cell lysates (Figure 7D). Next, these
Hs578TΔhTfR1 cells were transduced with the panel of
MMTV-based vectors carrying WT MMTV(C3H) Env,
mutant (G42E) Env, JUNV GP or TCRV GP. As a control,
one of the clones that carried no mutations at the hTFR1
and showed similar levels of hTfR1 expression to paren-
tal Hs578T cells was used. As expected, transduction
efficiency of JUNV GP-pseudotyped vectors was com-
promised in Hs578TΔhTfR1 cells compared to cells ex-
pressing hTfR1 (Figure 8A). Further, TCRV GP vector
transduction rates were unaffected by hTfR1 expression
(Figure 8A) [29,30]. In contrast, MMTV-based vectors
carrying either WT or mutant MMTV(C3H) Env trans-
duced Hs578TΔhTfR1 cells with similar efficiency to
cells expressing hTfR1 (Figure 8A).
The ability of MMTV-based vectors carrying either WT
or mutant MMTV(C3H) Env to transduce Hs578TΔhTfR1
cells was completely blocked after pre-incubating with
neutralizing goat anti-MMTV antibodies (Figure 8B). In
contrast, pre-treatment of the virions with non-specific
serum had no effect on the ability of these vectors to infect
Hs578TΔhTfR1 cells (Figure 8B). Importantly, TCRV GP
pseudotyped vectors, pre-incubated with the anti-MMTV
antibodies, were still able to transduce Hs578TΔhTfR1
cells (Figure 8B), ruling out nonspecific infection inhib-
ition activity of the serum. These results suggest that
MMTV-mediated infection of Hs578TΔhTfR1 cells relies
on a specific interaction of the viral envelope with a cell
surface receptor, other than hTfR1. Furthermore, the incu-
bation of supernatants at 60°C for 10 minutes, prior to
transduction of hTfR1 knock-out cells, abrogated the in-
fectivity of vectors regardless of the Env used (Figure 8B),
showing that transmission of vector DNA is temperature
sensitive, as expected for vector transduction rather than
for other means of DNA transfer. Finally, the addition of
AZT (37 μM) to the culture medium of the transduced
Hs578TΔhTfR1 cells inhibited transduction (Figure 8B),
further demonstrating that the presence of vector
DNA in the transduced cells resulted from the reverse
transcription-dependent process as expected for vector
transduction.
Collectively, the knock-out experiments further sup-
port the concept that MMTV is capable of infecting
cells in the absence of TfR1. The identified mutation in
the receptor binding site of MMTV Env that emerged
as a result of positive selection in cells lacking the pri-
mary receptor, mTfR1, further amplified this pheno-
type. Therefore, we propose that a molecule(s) on the
cell surface, other than TfR1, is capable of mediating
entry of MMTV into cells and thus serves as an alter-
native receptor/coreceptor.
hTFR1 guide oligos for sgRNA











































Figure 7 Generation of hTfR1 knock-out cells using CRISPR/Cas9. (A) TFR1 locus on the human chromosome 3 targeted by CRISPR/Cas9. A sgRNA
consisting of 20-nt guide sequence (blue) and a scaffold (green). The guide sequence anneals with the DNA target (blue bar) upstream of PAM
(red). A red arrow points to the expected cleavage site. (B) Oligonucleotide sequences used for the generation and characterisation of Hs578TΔhTfR1
cells. (C) Detection of mutations in Hs578T clones generated by transduction of lentiCRISPR vector containing sgRNA targeting hTFR1and Cas9
nuclease. PCR products (1100 bp) containing the target site were denatured, re-annealed and probed with T7 endonuclease that recognizes
non-perfectly matched DNA. A cleavage product of ~600 bp indicates successful NHEJ-mediated mutation in at least one copy of hTFR1 (lanes
2–11). Analysis of 12 clones is shown; (the amount of PCR product loaded in lane 4 was lower than in other lanes). (D) Western blot analysis
of the hTFR1 knock-out Hs578T clone (−/−) together with controls including parental cells (WT) and a clone containing at least one copy of
non-mutated hTFR1(+/+). Cellular lysates were also probed for actin to ensure equal loading (bottom panel). (E) Sequence analysis of the
hTFR1 target site of the clone bearing mutations in all three copies of the target site in Hs578T cells.
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The data presented here demonstrate that MMTV(C3H)
released from persistently infected human cells [MMTV
(C3H)hp1] exhibits a markedly faster replication kinet-
ics in human cells than the parental virus. Specifically,MMTV(C3H)hp1 required four-times less time (21 days)
to infect every cell in cell culture, even-though infectious
doses equivalent to those used with viruses produced from
murine cells were used. Several mechanisms may explain







































































































Figure 8 hTFR1 knock-out Hs578T cells are susceptible to MMTV infection. (A & B) Target cells were transduced with MMTV-based vectors carrying
wild-type MMTV(C3H) Env, G42E MMTV(C3H) Env, JUNV GP or TCRV GP. Neutralization, heat inactivation and AZT treatment were performed as described
in materials and methods. Transduction of target cells was detected by FCM 3 days post infection The number of eGFP-expressing cells was counted
using forward scatter vs. fluorescence intensity in the FL1 channel (eGFP) plots. (A) Transduction levels were made relative to the value obtained for the
infected cells expressing detectable levels of hTfR1 and expressed as percentage of that control. (B) Transduction levels were made relative to the value
obtained for the infected cells and expressed as percentage of that control. The values shown are mean ± standard errors from three independent
experiments.
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rions; ii) pseudotyping with human genome-encoded enve-
lope protein(s); iii) recombination with human cellular DNA
or human endogenous proviral sequences; iv) selection
of a pre-existing quasispecies in the wild-type MMTV
population and v) random mutation event(s) followed
by selection of variants exhibiting faster replication kinetics
in human cells.
We believe that the first two mechanisms can be read-
ily ruled out. This conviction is based on the observation
that MMTV(C3H)hp1 virions contained surface antigen
determinants identical or very similar to those found on
MMTVs released from murine cells, as judged from the
complete neutralization of MMTV(C3H)hp1 infectivity
with the MMTV-specific antibodies. Similarly, real time
RT-PCR results, combined with single round infection
experiments, did not reveal significantly greater levels
of defective viruses in virus preparations generated in
murine and human cells, respectively. Furthermore,
MMTV(C3H)hp1 did not contain sequences from other
viruses or from the human genome, as determined by
sequences analysis. Instead, the MMTV(C3H)hp1 se-
quences (complete genomes with the exception of the
Gag-coding region containing a sequence precluding clon-
ing and growth in E. coli) originated from MMTV(C3H).
Thus, recombination with sequences of human origin
does also not account for the observed variation in the
speed of virus replication. Finally, upon further analysis,
MMTV(C3H)hp1 was found to carry an hA3G specific
signature of cytosine deamination. Hallmarks of the
hA3G-mediated cytosine deamination further substantiateour original hypothesis that MMTV(C3H) is capable of
productive infection of human cells. Additionally, the
hA3G-mediated mutagenesis may, at least in part, also ex-
plain the relatively long cultivation time required to detect
infection of every human cell in culture.
Next, we analysed whether a selection pressure shaped
genetic variation during replication in human cells. We
found that some regions within the MMTV(C3H)hp1
genome, including the segments of the env gene encod-
ing the RBD at the N-terminus of the SU domain, the
central part of SU and the N-terminal part of TM do-
main, were under strong positive (fixation) selection
pressure. Most of the point mutations identified in the
SU subunit-encoding portion of env were unique to the
MMTV(C3H)hp1 sequences and were not found in
other strains of MMTV. Additionally, the bulk of the
polymorphisms were unique to each individual proviral
plasmid clone. Several non-synonymous mutations were
found in the RBD. Some of these mutations were situ-
ated directly in a five-amino-acid stretch of polar and
hydrophobic residues, F40HGFR44, believed to constitute
the RBS [20]. These mutations in the RBS may thus alter
MMTV SU tropism and allow MMTV to adapt to a new
host range.
Of note, all MMTV(C3H)hp1 viruses, in contrast to
their parental virus MMTV(C3H), carried a glutamic
acid substituted for glycine at position 42 of SU (G42E)
(Figure 2B). This residue has been shown to map to the
outer surface of the SU domain and to occupy a position
within a concave surface [20], consistent with a role in re-
ceptor binding/interaction. The non-conservative alteration
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charged polar residue is expected to impose both electro-
static and steric effects on the RBS (Figure 2C). This muta-
tion may thus alter virus receptor use, giving rise to an
adapted virus capable of infecting heterologous cells with
increased efficiency. In HIV, mutations that alter the charge
in and around the predicted CD4-binding site in gp120 give
rise to variants that enter cells in a CD4-independent man-
ner, which enables the virus to expand its target cell range
[50]. Additionally, charge has long been recognized to differ
between R5-tropic and X4-tropic V3 loop sequences [51].
Mutations that alter the V3 loop charge have been shown
to play an important role in determining virus tropism i.e.
which coreceptor is used to mediate cell entry [52].
The introduction of charged glutamic acid in place of
glycine in the WT MMTV(C3H) Env greatly increased
the efficiency with which the MMTV recombinant vi-
rions transduced human cells. In contrast, G42E substi-
tution caused only a modest alteration in transduction
levels of mouse cells. Furthermore, MMTV recombinant
virions carrying glutamic acid at position 42 bound hu-
man cells more efficiently than virions carrying WT Env.
No difference in binding was, however, observed for
wild-type and mutant virions in mouse cells. These data
imply that MMTV(C3H) produced from murine cells is
able to adapt to a new host range, at least in part, by
shaping the receptor binding domain to optimize the
interaction with its receptor(s).
Studies carried out with MMTV(C3H) Env-pseudotyped
MLV viruses showed that mTfR1 is used by MMTV to ini-
tiate infection of mouse cells [5]. The human ortholog
(hTfR1), however, was reported as a molecule incapable of
mediating MLV/MMTV(C3H) entry, even though it
bound pseudovirus efficiently [6]. Therefore, we initially
hypothesized that MMTV(C3H) that replicates in human
cells adapts, by mutating RBS, to enable utilization of
hTfR1 for cell entry. Such a scenario would be reminiscent
of what has been reported for another group of viruses
that use TfR1 as their primary cellular receptor - New
World clade B Arenaviruses. These viruses are endemic to
rodent populations found in the Americas and each virus
has evolved compatibility with the specific TfR1 ortholog
encoded by its respective host species [18,28-30]. Several
of these viruses have, however, through changes in the
amino acid residues of the RBD, acquired compatibility
with hTfR1, which allows more efficient infection of
human cells and enables the zoonotic transmission to
humans [26,46].
However, in the case of MMTV, the G42E mutation
that resulted from adaptation to human cells did not
confer hTfR1 dependence. This belief is based on the fol-
lowing evidence. First, the transient expression of hTfR1
in rodent (CHO) cells did not increase susceptibility to
MMTV-based vectors carrying the mutant Env relativeto vectors carrying WT Env. Second, human (Hs578T)
cells, in which the TfR1 expression has been down-
modulated using hTFR1-targeted siRNA did not exhibit
decreased susceptibility to MMTV-based vectors carry-
ing the mutant Env relative to vectors carrying the WT
Env. Third, MMTV-based vectors carrying mutant
MMTV(C3H) Env transduced hTFR1 knock-out human
Hs578T cells with efficiency similar to cells expressing
hTfR1. Additionally, when the binding rates of WT and
mutant MMTV Env-proteins (expressed in 293 T cells)
to a His-tagged recombinant-hTfR1 protein (immobi-
lized on a His-Ab coated biosensor) were assessed using
the BLItz System (ForteBio), the kinetic characteristics
of MMTV Env with and without the G42E mutation
showed no detectable differences in the interaction with
hTfR1 (data not shown).
Even-though the G42E mutation in the RBS does not
adapt MMTV to using hTfR1 for cell entry, it clearly
shapes the receptor binding domain to optimize the
interaction with its (as yet unknown) receptor(s) as evi-
denced by an enhanced infectivity of virions carrying the
G42E Env. This interaction could be neutralized by spe-
cific anti-MMTV serum further supporting the concept
that a specific interaction of viral envelope with a cell
surface receptor, other than hTfR1, mediates entry into
human cells.
The concept of an alternate receptor is further sup-
ported by other evidence. This includes the observation
that feline TfR1, derived from the most susceptible cell
line, CrFK, does not make cells susceptible to MMTV
infection [53]. Thus, feline cells must express another
molecule, different from TfR1 that enables the virus to
enter the cytoplasm. Further evidence comes from stud-
ies of cell entry of the non-pathogenic New World are-
naviruses. They typically use TfR1 orthologs of their host
species as receptor molecule. However, like MMTV, they
have been reported to relatively efficiently enter human
cells in an TfR1 independent manner using so far un-
identified alterantive receptor(s) [29,30]. Additionally,
the usage of more than one cell surface molecule as re-
ceptor is not rare and it has been reported for a number
of viruses including SARS coronavisus and enterovirus
71 [54,55]. Some viruses seem to exhibit an even more
complex receptor dependency that involves engagement
with multiple cell surface components. An example is
hepatitis C virus (HCV), which in addition to attach-
ment factors such as HS and L-SIGN also requires the
co-expression of four proteins (CD81, SR-B1, claudin-1
and occludin) for entry into cells (reviewed in [56]).
Another variation is the use of both a primary and a
secondary/co-receptor for cell entry. HIV-1 is a prime
example of such a process, since it requires the co-
expression of co-receptors (CCR5 or CXCR4), in addition
to the primary receptor CD4, for cell entry (reviewed in
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with attachment factors to bind to the cell surface before
interacting with the true receptor, such as the binding of
HIV-1 to syndecans, which enhances virus entry into mac-
rophages [58]. In the case of MMTV, an alternative recep-
tor may substitute for hTfR1, function in conjuction with
TfR1 in a manner similar to the HCV multiple cell surface
component dependency, or function down-stream of TfR1
in manner analogous to the HIV1 co-receptors. Work to
identify the attachment receptor used by MMTV to enter
human cells and initiate infection is currently ongoing.
Conclusion
The replication of MMTV(C3H) in human cells led to
the adaptation of the virus to its new host by shaping
the receptor binding domain to optimize the interaction
with its receptor(s). Our data explain the mechanism en-
abling MMTV to form ‘host-range variants’ in non-
murine cells that has been known for a long time, the
basis of which remained obscure. The receptor mediat-
ing infection of human cells remains to be identified as
we ruled out engagement of hTfR1 on the entry process.
The identified mutation (G42E) in the receptor binding
site that has emerged as a result of positive selection
pressure in human cells may serve as a marker of
MMTV replication in human cells.
Methods
Cell culture
HEK293T (ATCC CRL-3216), Hs578T (ATCC HTB-126),
NMuMG (ATCC CRL-1636), CHO-K1 (ATCC CCL-61)
and Mm5MT (ATCC CRL-1637) cells were maintained in
DMEM medium supplemented with 10% fetal bovine
serum (FBS). All cultured cells were maintained at 37°C in
humidified air containing 5% CO2.
Generation of Hs578T cells expressing EGFP
To generate an Hs578T-EGFP stable cell line, expressing
the green fluorescent reporter protein (EGFP) and the
neomycin resistance marker, Hs578T cells (plated at a
density of 2.4 × 105 cells per well of a six-well plate one
day before transfection) were transfected with 1 μg of
pCMV-EGFP vector (Clontech) using the TurboFect
transfection reagent (Thermo Scientific). Twenty-four
hours post-transfection, normal growth medium was re-
placed with medium containing G418 (400 μg/ml; Invitro-
gen) and the cells were cultured for two weeks. The
expression of EGFP in G418-resistent cells was analysed
by UV microscopy and FCM.
Generation of hTFR1 knock-out HS578T cells
hTFR1 was knocked out in Hs578T cells using the lenti-
CRISPR vector system as described before [49]. Oligo-
nucleotide primers specific for either hTFR1 (Figure 7A &B) or egfp were designed according to Shalem et al. [49].
The gene specific oligos were phosphorylated at the 5′
end using T4 polynucleotide kinase (PNK), annealed
together giving rise to a double stranded insert carrying
cohesive ends compatible with BsmBI-generated restric-
tion sites. Reactions were carried out in a total volume of
10 μl containing 100 μM of each oligo, 1x T4 Ligation
Buffer (NEB) and 5 units T4 PNK (NEB). After the first
incubation at 37°C for 30 minutes, the oligos were denatu-
rated at 95°C for 5 min and annealed together by gradually
ramping down temperature (−5°C/min) to 25°C. The lenti-
CRISPR vector was digested with BsmBI (NEB) to remove
a spacer sequence and ligated with the double stranded in-
sert. To produce lentivirus vector, 7.5 x 105 HEK293T cells
(6-well plate) were co-transfected with 1 μg lentiCRISPR
plasmid, 0.8 μg packaging construct (pLP1, Invirogen),
0.6 μg Rev expression construct (pLP2, Invitorgen) and
0.3 μg VSV-G Env-encoding plasmid (pHCMV-G). Trans-
fections were performed using the calcium phosphate
method. Thirty-six hours post-transfection, the virus-
containing supernatants were harvested, filtered (0.45 μm,
Sarstedt) and 4 serial dilutions (undiluted, 1:10, 1:100 and
1:1000) prepared. For transduction, target cells (Hs578T
or Hs578T-EGFP) were seeded at a density of 5 x 104 cells
per well (6-well plate), one day before transduction. The
increasing dilutions of the filtered virus supernatant was
added to cells together with polybrene (8 μg/ml) and re-
placed with fresh medium after 2 hours. Puromycin
(0.3 μg/mL) was added to the cells 16 hours post transduc-
tion. Hs578T-EGFP cells transduced with lentiCRISPR-
based vector particles carrying sgRNA targeting egfp were
maintained for 11 days and analysed by UV microscopy
and FCM. Hs578T cells transduced with lentiCRISPR-
based vector particles carrying sgRNA targeting hTFR1
were maintained for 14 days in the puromycin-containing
medium. Then, single clones were expanded, genomic
DNA extracted and analysed by a T7 endonuclease I assay
followed by DNA sequencing. For the T7 endonuclease
assay the primers listed in Figure 8A were used to generate
an 1100 bp PCR product encompassing the target site.
Cycling conditions consisted of 94°C for 2 min, followed
by 35 cycles of 94°C for 30 s, 58°C for 30 s, 72°C for 40 s,
and a final extension of 7 min at 72°C. The PCR products
were column purified and 500 ng of DNA per sample were
subjected to the following hybridisation reaction: 95°C for
5 min, ramped down to 85°C at −2°C /s and ramped down
further to 25°C at −0.1°C/s. The products were subse-
quently digested with 1 unit of T7 endonuclease (NEB) in
a 10 μl reaction volume for 30 min at 37°C. The mixture
was then resolved on a 2% agarose gel. The amplicons
carrying non-perfectly matched DNA (digested with T7
endonuclease) were cloned into the pCR2.1 plasmid
[TA cloning kit (Invitrogen)] and at least six clones
analysed by sequencing.
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egfp-containing MMTV recombinant virions carrying
one of the following envelope proteins MMTV Env,
amphotropic MLV Env, Junin GP or Tacaribe GP were
prepared in HEK293T cells as described before [39] and
used for transduction of target cells. Briefly, 7.5 x 105
cells (6-well plate) were co-transfected with a packaging
construct (pCMgpRRE17; 0.8 μg), an MMTV vector
plasmid (pRRpCeGFPWPRE25; 1 μg), a Rev expression
construct (pLP2; 0.6 μg) and a construct expressing either
MMTV(C3H)Env (0.3 μg), amphotropic MLVEnv (pAlf;
0.3 μg) [59], a pathogenic clade B arenavirus GP (JUNV;
0.3 μg) [30] or a non-pathogenic clade B arenavirus GP
(TCRV; 0.3 μg) [30]. Thirty-six hours post-transfection,
the virus-containing supernatants were harvested, filtered
(0.45 μm, Sarstedt) and used for transduction or stored at
−80°C. Target cells for transduction were seeded at a dens-
ity of 5 x 104 cells per well (6-well plate), one day before
transduction. The vector containing supernatant was
applied onto cells together with polybrene (8 μg/ml) and
replaced with fresh medium after 2 hours. Three days
post-transduction, cells were analysed by FCM.
Infections with MMTV(C3H) virus from Mm5MT
Filtered (0.45 μm, Sarstedt) cell culture fluids from
dexamethasone- stimulated (DEX; 10−6 M; Sigma-Aldrich)
Mm5MT cells (producing infectious MMTV(C3H) parti-
cles) (6.5 x 104 RNA copies) were used to infect target cells
seeded at a concentration of 5 x 104 cells per well (6-well
plate), one day before infection. The supernatant was
added to cells together with polybrene (8 μg/ml) and re-
placed with fresh medium after 2 hours. For single round
infection experiments, infected cells were cultured for one
week and analysed by PCR as described below. For time-
course experiments, infected Hs578T cells were further
cultivated in cell culture medium either supplemented or
not with DEX (10−6 M) for 7–16 weeks. Semi-quantitative
LTR-gag-specific PCR and qPCR was used to quantify
proviral DNA loads during the course of the experiment.
To directly demonstrate the production of infectious
MMTV particles from persistently infected Hs578T cells
[MMTV(C3H)hp1], supernatants from the infected cells
cultured with DEX for six weeks were filtered and used to
infect naive, uninfected target cells. The LTR-gag PCR was
employed to monitor the presence of proviral sequences
in the second round infected cells. For all infection experi-
ments normalized virus titers (6.5 x 104 RNA copies) were
used to infect target cells seeded in 6-well plates.
Neutralization of viral infectivity, heat inactivation and
AZT treatment
In infection neutralization experiments, vector/virus har-
vested from producer cells was incubated with polyclonal
goat anti-MMTV antiserum (1:500; kindly provided by S.Ross) or non-specific serum (1:500) on ice for 30 min
before infection. In heat inactivation experiments,
virus/vector was incubated at 60°C for 10 min prior to
infection. In 3′-azido-3′-deoxythymidine (AZT) treat-
ment experiments, AZT (37 μM) was added to naive
cells together with the virus inoculum. After 2 hours
incubation at 37°C, the supernatant was replaced with
fresh medium containing AZT (37 μM).
Heparan sulfate competition assay
MMTV-based vector particles carrying either WT Env
or the G42E mutant Env were incubated with the indi-
cated amount of heparan sulfate (Sigma-Aldrich) at 37°C
for 1 h. Polybrene (8 μg/ml) was added, and this mixture
used to infect Hs578T cells. After incubation for 2 h at
37°C, the cells were re-fed with fresh medium. Three
day post infection, cells were analysed for infection by
FCM.
Virus binding assay
Virus binding assay was performed as previously de-
scribed [20]. Briefly, MMTV recombinant virions carry-
ing either WT Env or G42E Env were generated as
described above. The vector particles were concentrated
by ultracentrifugation at 20,000 rpm for 2 h in an SW40
rotor, resuspended in 200 μl of phosphate-buffered sa-
line (PBS, pH 7.4) containing 2% FBS and 1 mM EDTA
(PBS-FE). Relative quantities of WT Env- and G 42E
Env-carrying virions in the preparations were deter-
mined by Western blotting using anti-MMTV CA anti-
body and serially diluted virus stocks. Single-cell
suspensions of Hs758T or NMuMG cells were prepared
by incubation of the cells with PBS-FE for 15 min,
followed by vigorous pipetting. Then, equal amounts of
virus particles containing either WT Env or G42E Env
(normalized based on Western blot results) was incu-
bated with 2.5 × 105 cells in the presence of Polybrene
(8 μg/ml) at 4°C for 1 h. The cells were washed three
times and resuspended in 100 μl of ice-cold PBS con-
taining 1% FBS and 0.2% sodium azide. Then, 100 μl of
a 1:100 dilution of goat anti-MMTV polyclonal anti-
serum was added and incubated for additional 30 min at
4°C. The cells were washed three times and incubated
with 100 μl of fluorescein isothiocyanate (FITC)-conju-
gated rabbit anti-goat immunoglobulin antibody. The
cells were washed three times, and analysed by FCM.
Subtilisin A treatment
Virions that remain attached to the cell surface of the
MMTV vector producing cells were quantified following
subtilisin A treatment as previously described [60]. Briefly,
transfected HEK293T cells (6 cm dishes) producing re-
combinant virions carrying either WT Env or G42E Env
were washed twice with PBS, once with subtilisin A buffer
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treated with 500 μl of 1 mg/ml subtilisin A (Sigma-
Aldrich) for 3 minutes at room temperature. Subtilisin
A treatment was stopped by adding DMEM containing
10% FCS, 5 mM PMSF and 20 mM EGTA. Virions re-
leased after subtilisin A treatment as well as virions
constitutively released from cells were concentrated by
ultracentrifugation (20,000 rpm for 2 h in an SW40
rotor). The virus pellets were resuspended in 50 μl of
lysis buffer (140 mM NaCl, 20 mM Tris pH 8.0, 1%
Triton X-100) and 10 μl of the resuspended pellets
was subjected to SDS-PAGE followed by Western
blotting analysis with anti-MMTV-CA antibodies.
Western Blot
Equivalent protein content of whole cell lysates (measured
using DC Protein Assay; Bio-Rad) or equal volumes of
concentrated MMTV vectors were resolved using a 12%
polyacrylamide gel and transferred to Hybond-P mem-
branes (GE healthcare). The membranes were probed with
the following antibodies: for detection of TfR1 – the rabbit
anti-transferrin receptor antibody (Abcam: ab84036; di-
lution 1:1000), for detection of beta-actin – the rabbit
anti-actin antibody (Sigma-Aldrich: A2066; dilution:
1:100), for detection of MMTV capsid protein – the
rabbit anti-MMTV-CA antibody (Michael Sakalian; dilu-
tion: 1:4000), for detection of MMTV SU and TM sub-
units of MMTV Env – the rabbit anti-gp52/36 (Janet
Butel; dilution 1:12000). The horseradish peroxidise-
konjugated swine anti-rabbit IgG (DAKO: P0399; dilution
1:10000) secondary antibody was used as secondary anti-
body followed by incubation with the ECL Prime Western
Blotting Detection Reagent Kit (GE Healthcare). Lumines-
cence signals were detected by exposure to Amersham
hyperfilm™ (GE healthcare) and/or by scanning using
LI-COR C-DIGIT blot scanner, which also allows quan-
tification of signals.
Semi-quantitative PCR
Genomic DNA (gDNA) was isolated from cells using the
QIAgen DNeasy Blood and Tissue Kit (Qiagen). The pres-
ence of MMTV proviral DNA in infected cells was de-
tected by PCR using primers designed to amplify a 717 bp
long segment spanning the MMTV LTR-gag region (935 F:
5′-AAG ACG ACA TGA AAC AAC AG-3′; 1637R: 5′-
CCC AGT TCC AAT GGC TCA CCG TAA-3′). 200 ng
of gDNA was used as a template for amplification. Cycling
conditions consisted of initial denaturation at 94°C for
2 min, followed by 35 cycles of 94°C for 30 s, 58°C for
1 min, 72°C for 40 s, and a final extension at 72°C for
7 min. Equal loading of each PCR reaction was controlled
using a GAPDH-specific primer pair (GAPDH F: 5′-ATG
GCT CCT GCA CCA CCA AC-3′; GAPDH R: 5′-CGC
CTG CTT CAC CAC CTT CT-3′) in a PCR reaction (only25 cycles) carried out with the identical sample amounts as
in the MMTV-specific PCR.
Quantitative PCR
Proviral loads in infected cells were quantified by a Real-
time TaqMan PCR using primers targeting the 5′ end of
the MMTV env. 100 ng of gDNA was amplified using
the following set of primers: MMTV 01 F: 5′-GGA
AAG TCC GGA GGA TGA ATC TA-3′, MMTV 02R:
5′-CTC CGC TTC GGA GAT TAA CG-3′ and a Taq-
Man probe: 5′-FAM-CAT CAA AGA GAA GAC GGC
TTG GCA ACA TC-TAMRA-3′. In each TaqMan ex-
periment, a standard was run consisting of a serially di-
luted plasmid carrying a molecular clone of MMTV
(pGR102) [61]. Cycling conditions consisted of 95°C for
2 min followed by 40 cycles of 95°C for 30 s and 60°C
for 1 min. The threshold cycle (Cτ) was measured for
each well and a standard curve was plotted using the
threshold cycle values of the serially diluted plasmid
DNA. Equal loading of PCR reactions was verified using
a TaqMan Real-time PCR specific for the human APOB
gene using the following primers and a TaqMan probe:
hAPOB F: 5′-TTC TTA CCA CAC ATC TCT TGA TTC
TCT T-3′, hAPOB R: 5′-GGA CTT CAC TGG ACA
AGG TCA TAC T-3′ and TaqMan probe: 5′-FAM-CAC
TCG TCC AGG TGC GAA GCA GAC T-3′. Identical
PCR conditions as outlined above were employed.
Amplification of viral RNA or proviral DNA followed by
sequencing
gDNA was isolated from Hs578T cells two weeks after
infection with MMTV(C3H)hp1 virus harvested from
persistently infected Hs578T cells. Viral RNA was ex-
tracted from supernatants of Mm5MT cells. TRI Reagent
(Sigma-Aldrich) was used for extractions. For cDNA
synthesis, RNA treated with DNAse I (TURBO DNA-
free kit; Ambion) was reverse transcribed using a primer
9877_R (5′-TCA GCA CTC TTT TAT ATC TTG G-3′)
and Superscript II reverse transcriptase (Invitrogen).
gDNA and cDNA were subsequently used for a long-
template PCR (Expand Long Template PCR system;
Roche), using primers 3722_F (5′-CGG GGT ACC GGC
TCA GAA GGC TTC GGA TC-3′) and 9761_R (5′-
ATA AGA ATG CGG CCG CGG CTC AGA AGG CTT
CGG ATC-3′), carrying Acc65I and NotI restriction sites
(italics), respectively. The resulting PCR fragments were
cloned into the corresponding sites of the pcDNA3 vector
(Invitrogen) and sequenced using overlapping primers
available from the authors upon request.
Knock-down of hTFR1 by small interfering RNA
Hs578T cells (plated at a density of 3 × 105 cells per well
of a six-well plate, one day before transfection) were trans-
fected overnight with human TFRC SMARTpool (25 nM,
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siRNA using DharmaFECT (Thermo Scientific). Forty-
eight hours post-transfection, the cells were either infected
with wild-type MMTV(C3H) virus or transduced with
egfp-containing MMTV-based vector particles carrying
the WT or mutant (G42E) MMTV(C3H) Env. Infection of
target cells with MMTV(C3H) virus was assessed by
the LTR-gag PCR one week after infection. Transduction
of target cells with egfp-carrying MMTV vectors was
assessed by FCM 72 hours post-transduction.TFR1 overexpression
CHO and Hs578T cells (plated at a density of 2 × 105 cells
per well of a six-well plate, one day before transfection)
were transfected with 4 μg of a mTfR1 expression vector
(pcDNA3.1-mTfR1; kindly donated by S. Ross), a hTfR1
expression vector (pcDNA3.1-hTfR1; kindly donated by P.
Cannon) or pcDNA3.1 parental vector using the Turbo-
Fect transfection reagent (Thermo Scientific). Forty-eight
hours post-transfection, the cells were either infected
with wild-type MMTV(C3H) virus or transduced with
egfp-containing MMTV-based vector particles carrying
the WT or mutant (G42E) Env. Infection/transduction
was assessed as described above.Additional files
Additional file 1: Figure S1. Infection of target cells with cell-free virus
from supernatants of murine producer cells. (A) CHO cells transfected
with hTfR1 or mTfR1expression plasmids were infected with cell-free
virus from supernatants of murine producer cells [Mm5MT – MMTV(C3H)].
Expression of hTfR1 was confirmed by western blotting (insets); mTfR1 was
not recognised by the α-TfR1 antibody (ab137944, Abcam). (B) Hs578T cells
transfected with hTFR –specific siRNA or control siRNA were infected with
cell-free virus from supernatants of murine producer cells [Mm5MT –
MMTV(C3H)]. hTfR1 knock-down was confirmed by western blotting (inset).
(A & B) Genomic DNA was isolated from infected cells one week post-
infection and analysed by PCR for the presence of MMTV sequences. -ve:
non-transduced Hs578T cells. +ve: producer cells. Equal DNA loading was
controlled in the PCR assay with GAPDH-specific primers (bottom panels).
Additional file 2: Figure S2. Truncated protein products resulting from
the mutations introduced into the hTfR1 locus using the CRISPR-Cas9 system.Abbreviations
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